Ohara T, Ogata H, Fujiyama J, Murata Y, Abe J, Kakuta K, Hayamizu S, Kameyama S, Yoshida Y
Tohoku J Exp Med. 1985 Jun;146(2):237-49. doi: 10.1620/tjem.146.237.
Prostaglandin E1 (PGE1) was administered to 27 infants in whom pulmonary or systemic blood flow was entirely or significantly dependent upon the patency of the ductus arteriosus. In 12 patients with pulmonary atresia or severe pulmonary stenosis, PGE1 infusion was followed by an improvement in hypoxemia and acidemia (group I). In 2 patients with left ventricular outflow-tract obstruction, PGE1 infusion was followed by an improvement in arterial blood pressure, peripheral perfusion and urine output (group II). In 5 patients with d-transposition of the great arteries and intact ventricular septum who had persistent severe hypoxemia after creation of an interatrial communication, PGE1 infusion improved the arterial oxygenation with dilatation of the ductus arteriosus (group III). Seven patients (3 of group I, 2 of group II and 2 of group III) failed to respond to PGE1. There were no fatal side effects. It is concluded that PGE1 therapy is highly effective in stabilizing pre-operative conditions of infants with ductus-dependent congenital heart disease.
对27例肺循环或体循环血流完全或显著依赖动脉导管通畅的婴儿给予前列腺素E1（PGE1）。在12例肺动脉闭锁或严重肺动脉狭窄患者中，输注PGE1后低氧血症和酸血症得到改善（I组）。在2例左心室流出道梗阻患者中，输注PGE1后动脉血压、外周灌注和尿量得到改善（II组）。在5例大血管d型转位且室间隔完整、在建立房间隔交通后仍持续严重低氧血症的患者中，输注PGE1通过扩张动脉导管改善了动脉氧合（III组）。7例患者（I组3例、II组2例和III组2例）对PGE1无反应。无致命副作用。结论是，PGE1治疗在稳定依赖动脉导管的先天性心脏病婴儿的术前状况方面非常有效。
